RT Journal Article
SR Electronic
T1 Laboratory Testing Implications of Risk-Stratification and Management for Improving Clinical Outcomes of COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.12.20129098
DO 10.1101/2020.06.12.20129098
A1 Liu, Caidong
A1 Wang, Ziyu
A1 Li, Jie
A1 Xiang, Changgang
A1 Wu, Lingxiang
A1 Wu, Wei
A1 Hou, Weiye
A1 Sun, Huiling
A1 Wang, Youli
A1 Nie, Zhenling
A1 Gao, Yingdong
A1 Zhang, Ruisheng
A1 Xia, Xinyi
A1 Wang, Qianghu
A1 Wang, Shukui
YR 2020
UL http://medrxiv.org/content/early/2020/06/14/2020.06.12.20129098.abstract
AB The high mortality rate of COVID-19 patients is mainly caused by the progression from mild to critical illness. To identify the key laboratory indicators and stratify high-risk COVID-19 patients with progression to severe/critical illness, we compared 474 moderate patients and 74 severe/critical patients. The laboratory indicators, including lactate dehydrogenase (LDH), monocytes percentage, etc. were significantly higher in the severe/critical patients (P <0.001) and showed a noticeable change at about a week before the diagnosis. Based on these indicators, we constructed a risk-stratification model, which can accurately grade the severity of patients with COVID-19 (accuracy = 0.96, 95% CI: 0.94 - 0.989, sensitivity = 0.98, specificity = 0.84). Also, compared with non-COVID-19 viral pneumonia, we found that COVID-19 had weaker dysfunction to the heart, liver, and kidney. The prognostic model based on laboratory indicators could help to diagnose, monitor, and predict severity at an early stage to those patients with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by the National Natural Science Foundation of China (Grant Nos. 81572893, 81972358, 91959113), Key Research& Development Program of Jiangsu Province (Grant Nos. BE2017733).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the department of Ethical Committee, First People's Hospital of Jiangxia District of Wuhan, and the Ethical Committee of Nanjing Medical University (2020-511).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.